Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.jinf.2021.02.023

http://scihub22266oqcxt.onion/10.1016/j.jinf.2021.02.023
suck pdf from google scholar
33639176!7904476!33639176
unlimited free pdf from europmc33639176    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33639176      J+Infect 2021 ; 82 (4): 58-66
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy #MMPMID33639176
  • Petrone L; Petruccioli E; Alonzi T; Vanini V; Cuzzi G; Najafi Fard S; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Grifoni A; Antinori A; Vergori A; Ippolito G; Cantini F; Goletti D
  • J Infect 2021[Apr]; 82 (4): 58-66 PMID33639176show ga
  • OBJECTIVE: Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform. METHODS: We evaluated baricitinib effect on the IFN-gamma-release and on a panel of soluble factors by multiplex-technology after stimulating whole-blood from 39 COVID-19 patients with SARS-CoV-2 antigens. Staphylococcal Enterotoxin B (SEB) antigen was used as a positive control. RESULTS: In-vitro exogenous addition of baricitinib significantly decreased IFN-gamma response to spike- (median: 0.21, IQR: 0.01-1; spike+baricitinib 1000?nM median: 0.05, IQR: 0-0.18; p < 0.0001) and to the remainder-antigens (median: 0.08 IQR: 0-0.55; remainder-antigens+baricitinib 1000?nM median: 0.03, IQR: 0-0.14; p?=?0.0013). Moreover, baricitinib significantly decreased SEB-induced response (median: 12.52, IQR: 9.7-15.2; SEB+baricitinib 1000?nM median: 8, IQR: 1.44-12.16; p < 0.0001). Baricitinib did modulate other soluble factors besides IFN-gamma, significantly decreasing the spike-specific-response mediated by IL-17, IL-1beta, IL-6, TNF-alpha, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1beta (p?/=1?x?10(3)/microl. CONCLUSIONS: Exogenous addition of baricitinib decreases the in-vitro SARS-CoV-2-specific response in COVID-19 patients using a whole-blood platform. These results are the first to show the effects of this therapy on the immune-specific viral response.
  • |*COVID-19 Drug Treatment[MESH]
  • |Azetidines[MESH]
  • |Cytokines[MESH]
  • |Humans[MESH]
  • |Purines[MESH]
  • |Pyrazoles[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box